The online version of this article (https://doi.org/10.1007/s00432-019-03091-y) contains supplementary material, which is available to authorized users.
Viola Heinzelmann-Schwarz and André B. Kind contributed equally.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Malignant mixed Mullerian tumors of endometrial (MMMT-E) and ovarian (MMMT-O) origin are associated with poor prognosis. Suggestively epithelial-driven tumors, their treatment has shifted from anthracycline or ifosfamide-based towards taxane-based chemotherapy. It remains unclear whether this change associates with better outcomes.
A conjoined Australian and Swiss patient cohort of MMMT-E (N = 103) and MMMT-O (N = 17) was compared to patients with adenocarcinoma of the endometrium (EC, N = 172) and ovary (OC, N = 189). Clinicopathological characteristics, FIGO stage, first-line treatment, and patient outcomes were analyzed. The generated hypothesis was verified in an US-American cohort with high-grade serous ovarian cancer (HGSOC, N = 1290) and MMMT-O (N = 450) using immunohistochemistry and next-generation sequencing.
Early stage I/II MMMT-E showed a survival plateau after 2.5 years, with no recurrence or death observed afterwards. Relapse-free survival was significantly worse in MMMT-E treated with platinum/taxanes (P = 0.024) compared to non-taxane regimen. Hypothesizing that also MMMT-O might benefit from an adjuvant non-paclitaxel regimen, a second independent cohort of MMMT-O and HGSOC patients was examined. p53 mutations dominated in both cancers with comparable frequency. PI3KCA and KRAS mutations were less frequent: they were more frequent in MMMT-O than in HGSOC (P = 0.015 and P = 0.018, respectively). MMMT-O responded better to a combination of carboplatin with anthracyclines than with taxanes (73.9% vs. 39.4%).
Early stage I/II MMMT-E patients have excellent prognosis if no recurrence has appeared within the first 2.5 years. In MMMT-E, platinum/anthracycline or ifosfamide regimen associated with better outcomes than platinum/taxanes regimens. This might also apply to MMMT-O.
Aghajanian C, Sill MW, Secord AA et al (2012) Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. Gynecol Oncol 126:424–427 CrossRef
Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA et al (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer 24(Suppl 3):S55–S60 CrossRef
Campos SM, Brady WE, Moxley KM et al (2014) A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 133:537–541 CrossRef
Cantrell LA, Blank SV, Duska LR (2015) Uterine carcinosarcoma: a review of the literature. Gynecol Oncol 137:581–588 CrossRef
Duska LR, Garrett A, Eltabbakh GH et al (2002) Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. Gynecol Oncol 85:459–463 CrossRef
Einstein MH, Klobocista M, Hou JY et al (2012) Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol 124:26–30 CrossRef
Fowler JM, Blessing JA, Burger RA, Malfetano JH (2002) Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study. Gynecol Oncol 85:311–314 CrossRef
Gadducci A, Sartori E, Landoni F et al (2002) The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol 23:295–299 PubMed
Galaal K, van der Heijden E, Godfrey K et al (2011) Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2:CD006812
Gonzalez Bosquet J, Terstriep SA, Cliby WA et al (2010) The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol 116:419–423 CrossRef
Gorai I, Yanagibashi T, Taki A et al (1997) Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer 72:821–827 CrossRef
Homesley HD, Filiaci V, Markman M et al (2007) Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 25:526–531 CrossRef
Homesley HD, Filiaci V, Gibbons SK et al (2009) A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 112:543–552 CrossRef
Hoskins PJ, Le N, Ellard S et al (2008) Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol 108:58–62 CrossRef
Janssens J, Gallagher WM, Dean A et al (2017) Tumor profiling-directed precision cancer therapy—comparison of commercial and academic clinical utility. Int J Surg Surg Porced 2:123
Kernochan LE, Garcia RL (2009) Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 7:550–556 (quiz 557) CrossRef
Lacour RA, Euscher E, Atkinson EN et al (2011) A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer 21:517–522 CrossRef
Leiser AL, Chi DS, Ishill NM, Tew WP (2007) Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 105:657–661 CrossRef
Lorusso D, Martinelli F, Mancini M et al (2014) Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study. Int J Gynecol Cancer 24:1256–1261 CrossRef
Mackay HJ, Buckanovich RJ, Hirte H et al (2012) A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol 125:136–140 CrossRef
Mahdi H, Xiu J, Reddy SK (2015) Ovarian carcinosarcoma share similar molecular profile as ovarian serous carcinoma but not endometrial carcinosarcoma. J Clin Oncol 33:2015 CrossRef
Makker V, Abu-Rustum NR, Alektiar KM et al (2008) A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I–IV uterine carcinosarcoma. Gynecol Oncol 111:249–254 CrossRef
Manolitsas TP, Wain GV, Williams KE et al (2001) Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus. Cancer 91:1437–1443 CrossRef
McCluggage WG (2002) Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 12:687–690 CrossRef
Miller DS, Blessing JA, Schilder J et al (2005) Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 98:217–221 CrossRef
Miller BE, Blessing JA, Stehman FB et al (2010) A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 118:139–144 CrossRef
NCCN (2001) Uterine neoplasms. Pract Guidel Oncol 2001:1–48
Otsuki A, Watanabe Y, Nomura H et al (2015) Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit. Int J Gynecol Cancer 25:92–97 CrossRef
Schott AF, Perou CM, Hayes DF (2015) Genome medicine in cancer: what’s in a name? Cancer Res 75:1930–1935 CrossRef
Signorelli M, Chiappa V, Minig L et al (2009) Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. Int J Gynecol Cancer 19:1142–1146 CrossRef
Silverberg SG, Major FJ, Blessing JA et al (1990) Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9:1–19 CrossRef
Sutton G, Brunetto VL, Kilgore L et al (2000) A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 79:147–153 CrossRef
Sutton G, Kauderer J, Carson LF et al (2005) Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 96:630–634 CrossRef
Tanner EJ, Leitao MM, Garg K et al (2011) The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol Oncol 123:548–552 CrossRef
Tate Thigpen J, Blessing JA, DeGeest K et al (2004) Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 93:336–339 CrossRef
Vandenput I, Trovik J, Vergote I et al (2011) The role of adjuvant chemotherapy in surgical stages I–II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study. Int J Gynecol Cancer 21:332–336 CrossRef
Vorgias G, Fotiou S (2010) The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet 282:659–664 CrossRef
Wolfson AH, Brady MF, Rocereto T et al (2007) A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107:177–185 CrossRef
Yamada SD, Burger RA, Brewster WR et al (2000) Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 88:2782–2786 CrossRef
- Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
André B. Kind
Michael L. Friedlander
Neville F. Hacker
- Springer Berlin Heidelberg
Journal of Cancer Research and Clinical Oncology
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
Neu im Fachgebiet Onkologie
Mail Icon II